Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice

Autor: Irene Artuso, Mariateresa Pettinato, Antonella Nai, Alessia Pagani, Ugo Sardo, Benjamin Billoré, Maria Rosa Lidonnici, Cavan Bennett, Giacomo Mandelli, Sant-Rayn Pasricha, Giuliana Ferrari, Clara Camaschella, Léon Kautz, Laura Silvestri

Publikováno v: Haematologica, Vol 104, Iss 3 (2019)

Externí odkaz: https://doaj.org/article/7006108ef81a474cb5c49c5a3f4bf1b2

Anharmonicity and quantum nuclear effects in theoretical vibrational spectroscopy: a molecular tale of two cities

Autor: Riccardo Conte, Chiara Aieta, Giacomo Botti, Marco Cazzaniga, Michele Gandolfi, Cecilia Lanzi, Giacomo Mandelli, Davide Moscato, Michele Ceotto

Publikováno v: Theoretical Chemistry Accounts. 142

Anharmonic effects due to the shape of the molecular potential energy surface far from the equilibrium geometry are major responsible for the deviations of the actual frequencies of vibration from the harmonic estimates. However, anharmonic effects a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1968424d2e53257e58b51a1fdc0c76a
https://doi.org/10.1007/s00214-023-02993-y

Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia

Autor: Francesca Sanvito, Ylenia Paleari, Annamaria Aprile, Franck Chanut, Luigi Naldini, Fulvio Mavilio, Patrizia Cristofori, Claudia Rossi, Maria Rosa Lidonnici, Giuliana Ferrari, Giacomo Mandelli, Eugenio Montini, Andrea Calabria, Alessandro Ambrosi, Valentina Poletti, Francesca Tiboni, Michela Vezzoli, Carsten W. Lederer

Publikováno v: Mol Ther Methods Clin Dev
Mol Ther Methods Clin Dev, 2018, 11, pp.9-28. ⟨10.1016/j.omtm.2018.09.001⟩
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss, Pp 9-28 (2018)
Molecular Therapy-Methods & Clinical Development

Gene therapy clinical trials require rigorous non-clinical studies in the most relevant models to assess the benefit-to-risk ratio. To support the clinical development of gene therapy for β-thalassemia, we performed in vitro and in vivo studies for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91676d09e4f1d206a3e4150b26efc2f
https://doi.org/10.1016/j.omtm.2018.09.001

Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model

Autor: Giuliana Ferrari, Sandro Altamura, Martina U. Muckenthaler, Antonella Nai, Maria Rosa Lidonnici, Mariateresa Pettinato, Irene Artuso, Clara Camaschella, Giacomo Mandelli, Laura Silvestri

β-thalassemias are genetic disorders characterized by anemia, ineffective erythropoiesis, and iron overload. Current treatment of severe cases is based on blood transfusion and iron chelation or allogeneic bone marrow (BM) transplantation. Novel app

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6654d8815b0bce37b497de0a537d46e
https://europepmc.org/articles/PMC6302281/

Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced

Autor: Maria Rosa, Lidonnici, Annamaria, Aprile, Marta Claudia, Frittoli, Giacomo, Mandelli, Ylenia, Paleari, Antonello, Spinelli, Bernhard, Gentner, Matilde, Zambelli, Cristina, Parisi, Laura, Bellio, Elena, Cassinerio, Laura, Zanaboni, Maria Domenica, Cappellini, Fabio, Ciceri, Sarah, Marktel, Giuliana, Ferrari

Publikováno v: Haematologica. 102(4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88f8f376da110f2be693e5b72c0beff6
https://pubmed.ncbi.nlm.nih.gov/28034992